Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam S Cheifetz

Showing results (131-140 of 203) with videos related to

Pageof 21
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 3, 2017
Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of InfliximabKonstantinos Papamichael, Karen A Chachu, Ravy K Vajravelu, et al.
Expert Review of Clinical Pharmacology|February 11, 2026
Therapeutic drug monitoring for de-escalating anti-tumor necrosis factor therapy in patients with inflammatory bowel diseaseAjay Gade, Alessandra Saraga, Alfonso Elosua, et al.
Journal of Crohn'S & Colitis|January 29, 2019
Proactive Therapeutic Drug Monitoring of Adalimumab Is Associated With Better Long-term Outcomes Compared With Standard of Care in Patients With Inflammatory Bowel DiseaseKonstantinos Papamichael, Anna Juncadella, Danny Wong, et al.
Mayo Clinic Proceedings|January 7, 2014
Systematic analysis underlying the quality of the scientific evidence and conflicts of interest in interventional medicine subspecialty guidelinesJoseph D Feuerstein, Mona Akbari, Anne E Gifford, et al.
Inflammatory Bowel Diseases|February 9, 2020
Meta-analysis of Virtual-based Chromoendoscopy Compared With Dye-spraying Chromoendoscopy Standard and High-definition White Light Endoscopy in Patients With Inflammatory Bowel Disease at Increased Risk of Colon CancerMohammed El-Dallal, Ye Chen, Qianyun Lin, et al.
Inflammatory Bowel Diseases|July 2, 2024
Proactive Therapeutic Drug Monitoring Is Associated With Increased Drug Persistence in Patients With Inflammatory Bowel Disease Treated With Intravenous VedolizumabRachel Porth, Tina Deyhim, Samantha Zullow, et al.
Inflammatory Bowel Diseases|September 26, 2024
Proactive Therapeutic Drug Monitoring of Ustekinumab Is Associated With Increased Drug Persistence in Patients With Inflammatory Bowel DiseaseRachel Porth, Tina Deyhim, Grace Geeganage, et al.
Digestive Diseases and Sciences|December 9, 2025
Proactive Compared to Reactive Therapeutic Drug Monitoring Is Associated with Less Treatment Failure in Patients with Inflammatory Bowel Disease Treated with AdalimumabAjay Gade, Alessandra Saraga, Tina Deyhim, et al.
Inflammatory Bowel Diseases|August 26, 2025
Long-term Outcomes of Patients with Crohn's Disease Treated with RisankizumabGrace Geeganage, Ajay Gade, Alessandra Saraga, et al.
Journal of Pediatric Gastroenterology and Nutrition|February 20, 2024
Anti-infliximab antibodies and low infliximab levels correlate with drug discontinuation in pediatric inflammatory bowel diseaseNaamah Zitomersky, Lisa Chi, Enju Liu, et al.
Pageof 21

Showing results (131-140 of 203) with videos related to

Sort By:
Pageof 21
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 3, 2017
Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of InfliximabKonstantinos Papamichael, Karen A Chachu, Ravy K Vajravelu, et al.
Expert Review of Clinical Pharmacology|February 11, 2026
Therapeutic drug monitoring for de-escalating anti-tumor necrosis factor therapy in patients with inflammatory bowel diseaseAjay Gade, Alessandra Saraga, Alfonso Elosua, et al.
Journal of Crohn'S & Colitis|January 29, 2019
Proactive Therapeutic Drug Monitoring of Adalimumab Is Associated With Better Long-term Outcomes Compared With Standard of Care in Patients With Inflammatory Bowel DiseaseKonstantinos Papamichael, Anna Juncadella, Danny Wong, et al.
Mayo Clinic Proceedings|January 7, 2014
Systematic analysis underlying the quality of the scientific evidence and conflicts of interest in interventional medicine subspecialty guidelinesJoseph D Feuerstein, Mona Akbari, Anne E Gifford, et al.
Inflammatory Bowel Diseases|February 9, 2020
Meta-analysis of Virtual-based Chromoendoscopy Compared With Dye-spraying Chromoendoscopy Standard and High-definition White Light Endoscopy in Patients With Inflammatory Bowel Disease at Increased Risk of Colon CancerMohammed El-Dallal, Ye Chen, Qianyun Lin, et al.
Inflammatory Bowel Diseases|July 2, 2024
Proactive Therapeutic Drug Monitoring Is Associated With Increased Drug Persistence in Patients With Inflammatory Bowel Disease Treated With Intravenous VedolizumabRachel Porth, Tina Deyhim, Samantha Zullow, et al.
Inflammatory Bowel Diseases|September 26, 2024
Proactive Therapeutic Drug Monitoring of Ustekinumab Is Associated With Increased Drug Persistence in Patients With Inflammatory Bowel DiseaseRachel Porth, Tina Deyhim, Grace Geeganage, et al.
Digestive Diseases and Sciences|December 9, 2025
Proactive Compared to Reactive Therapeutic Drug Monitoring Is Associated with Less Treatment Failure in Patients with Inflammatory Bowel Disease Treated with AdalimumabAjay Gade, Alessandra Saraga, Tina Deyhim, et al.
Inflammatory Bowel Diseases|August 26, 2025
Long-term Outcomes of Patients with Crohn's Disease Treated with RisankizumabGrace Geeganage, Ajay Gade, Alessandra Saraga, et al.
Journal of Pediatric Gastroenterology and Nutrition|February 20, 2024
Anti-infliximab antibodies and low infliximab levels correlate with drug discontinuation in pediatric inflammatory bowel diseaseNaamah Zitomersky, Lisa Chi, Enju Liu, et al.
Pageof 21